Abstract
It is widely accepted that Aβ42 aggregation is a central event in the pathogenesis of Alzheimers disease. Aβ42 oligomers and fibrils cause the breakdown of neural circuits, neuronal death and eventually dementia. There are a number of physiological molecules that can protect Aβ42 from aggregation. Promoting such protective molecules and mechanisms against Aβ42 aggregation may be a novel direction in AD drug discovery. One of the most striking protective molecules is none other than Aβ40, which inhibits Aβ42 aggregation in a specific and dosage dependent manner. Aβ40 is a critical, built-in mechanism against Aβ42 aggregation. A number of other molecules and mechanisms also inhibit Aβ42 aggregation, such as heat shock proteins, L-PGDS, heme and methionine oxidation. The relevance of these protective mechanisms to AD pathogenesis and intervention is discussed.
Keywords: Amyloid-β peptide (Aβ), Alzheimer's disease (AD), protection, Aβ42 aggregation, Aβ40, NMR, heat shock protein, L-PGDS, heme, methionine oxidation
Current Alzheimer Research
Title: Protection Mechanisms Against Aβ42 Aggregation
Volume: 5 Issue: 6
Author(s): Y. Yan and C. Wang
Affiliation:
Keywords: Amyloid-β peptide (Aβ), Alzheimer's disease (AD), protection, Aβ42 aggregation, Aβ40, NMR, heat shock protein, L-PGDS, heme, methionine oxidation
Abstract: It is widely accepted that Aβ42 aggregation is a central event in the pathogenesis of Alzheimers disease. Aβ42 oligomers and fibrils cause the breakdown of neural circuits, neuronal death and eventually dementia. There are a number of physiological molecules that can protect Aβ42 from aggregation. Promoting such protective molecules and mechanisms against Aβ42 aggregation may be a novel direction in AD drug discovery. One of the most striking protective molecules is none other than Aβ40, which inhibits Aβ42 aggregation in a specific and dosage dependent manner. Aβ40 is a critical, built-in mechanism against Aβ42 aggregation. A number of other molecules and mechanisms also inhibit Aβ42 aggregation, such as heat shock proteins, L-PGDS, heme and methionine oxidation. The relevance of these protective mechanisms to AD pathogenesis and intervention is discussed.
Export Options
About this article
Cite this article as:
Yan Y. and Wang C., Protection Mechanisms Against Aβ42 Aggregation, Current Alzheimer Research 2008; 5 (6) . https://dx.doi.org/10.2174/156720508786898460
DOI https://dx.doi.org/10.2174/156720508786898460 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Concurrent Use of Antiretrovirals and Anticonvulsants in Human Immunodeficiency Virus (HIV) Seropositive Patients
Current Pharmaceutical Design Neurological Substrate of Central Auditory Processing Deficits in Children
Current Pediatric Reviews Identification of Novel Biomarker Candidates by Differential Peptidomics Analysis of Cerebrospinal Fluid in Alzheimers Disease
Combinatorial Chemistry & High Throughput Screening Multi-Target Directed Compounds with Antioxidant and/or Anti- Inflammatory Properties as Potent Agents for Alzheimer’s Disease
Medicinal Chemistry Immune Modulation of HIV Replication: Relevance to HIV Immuno- and Neuro-Pathogenesis
Current HIV Research Executive Function and Diabetes Mellitus - A Stone Left Unturned?
Current Diabetes Reviews Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Induced Pluripotent Stem Cell-Based Studies of Parkinson's Disease: Challenges and Promises
CNS & Neurological Disorders - Drug Targets Editorial
Current Medical Imaging Elucidating the Risk Factors for Progression from Amyloid-Negative Amnestic Mild Cognitive Impairment to Dementia
Current Alzheimer Research Psychopharmacological Treatment in Pathological Gambling: A Critical Review
Current Pharmaceutical Design The Perils, Pitfalls and Opportunities of Using High Sensitivity Cardiac Troponin
Current Medicinal Chemistry Strength and Weaknesses of Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease and Possible Detection of Overlaps with Frailty Process
CNS & Neurological Disorders - Drug Targets Role of Autophagy in Alzheimer’s Disease
Current Enzyme Inhibition Peptide Sequence Prediction Supported by Correlation-Associated Networks in Human Cerebrospinal Fluid
Combinatorial Chemistry & High Throughput Screening Animal Models for Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Omega-3 Polyunsaturated Fatty Acids in Alzheimers Disease: Key Questions and Partial Answers
Current Alzheimer Research Editorial [“Current Aging Science”: An Important Platform for Reporting Advances in Aging-related Research]
Current Aging Science Voice Markers of Lexical Access in Mild Cognitive Impairment and Alzheimer's Disease
Current Alzheimer Research Role of CNS Transporters in the Pharmacotherapy of HIV-1 Associated Neurological Disorders
Current Pharmaceutical Design